{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:25:30Z","timestamp":1793064330137,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["2019CHAL2729"],"award-info":[{"award-number":["2019CHAL2729"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018771","name":"Veracyte Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A22744"],"award-info":[{"award-number":["A22744"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020400","name":"John Black Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["MA-ETNA19-009"],"award-info":[{"award-number":["MA-ETNA19-009"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["MA-PM16-001"],"award-info":[{"award-number":["MA-PM16-001"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cell.2025.07.042","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T18:56:27Z","timestamp":1756234587000},"page":"5717-5734.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers"],"prefix":"10.1016","volume":"188","author":[{"given":"Emily","family":"Grist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dutey-Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazlina","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"DePaula Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwademilade","family":"Dairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanpreet","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wetterskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wingate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Nowakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Zakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisah B.","family":"Atako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Marafioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Urbanucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Fittall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-7983","authenticated-orcid":false,"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2025.07.042_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.07.042_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.07.042_bib3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.07.042_bib9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.07.042_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cell.2025.07.042_bib13","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","article-title":"SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer","volume":"28","author":"Swami","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2025.07.042_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2015.109","article-title":"The oncogene ERG: a key factor in prostate cancer","volume":"35","author":"Adamo","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.cell.2025.07.042_bib15","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac043","article-title":"Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial","volume":"6","author":"James","year":"2022","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.cell.2025.07.042_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","article-title":"Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial","volume":"32","author":"Hamid","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib21","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib22","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.cell.2025.07.042_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/jnci\/djn150","article-title":"Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer","volume":"100","author":"Setlur","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cell.2025.07.042_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147878","article-title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cell.2025.07.042_bib26","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1073\/pnas.0702507104","article-title":"Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity","volume":"104","author":"Saal","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2025.07.042_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.clgc.2020.08.004","article-title":"Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer","volume":"19","author":"Chipidza","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.cell.2025.07.042_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2025.07.042_bib29","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1158\/1078-0432.CCR-19-1587","article-title":"Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naive Primary Prostate Cancer","volume":"25","author":"Spratt","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2025.07.042_bib30","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-17-2745","article-title":"Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy","volume":"24","author":"Karnes","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2025.07.042_bib31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cell.2025.07.042_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2006.09.005","article-title":"Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators","volume":"10","author":"Hieronymus","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2025.07.042_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.cell.2025.07.042_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib35","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1002\/ijc.32430","article-title":"Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma","volume":"145","author":"Alshalalfa","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cell.2025.07.042_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2025.07.042_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12885-017-3729-z","article-title":"Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma","volume":"17","author":"Tsai","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cell.2025.07.042_bib39","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2021.3987","article-title":"Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer","volume":"7","author":"Aggarwal","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology\/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cell.2025.07.042_bib41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers","volume":"38","author":"Carter","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2025.07.042_bib43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41391-021-00416-2","article-title":"A transcriptomic model for homologous recombination deficiency in prostate cancer","volume":"25","author":"Weiner","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.cell.2025.07.042_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25624-1","article-title":"Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse","volume":"12","author":"Taavitsainen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.07.042_bib45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S1470-2045(16)30491-0","article-title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis","volume":"17","author":"Zhao","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib46","article-title":"Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.07.042_bib47","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG\/RTOG 9601 Randomized Clinical Trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib49","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2025.07.042_bib50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: Tumor Suppressor and Metabolic Regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.cell.2025.07.042_bib51","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial","volume":"40","author":"Rush","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193257","article-title":"PTEN suppresses axon outgrowth by down-regulating the level of detyrosinated microtubules","volume":"13","author":"Kath","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cell.2025.07.042_bib53","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2025.07.042_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","article-title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","volume":"567","author":"Rueda","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.07.042_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cell.2025.07.042_bib56","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","article-title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial","volume":"33","author":"Dal Pra","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib57","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1200\/PO.19.00388","article-title":"Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial","volume":"4","author":"Gilson","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib58","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-22-0851","article-title":"Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer","volume":"28","author":"Sowalsky","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2025.07.042_bib59","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/1055-9965.EPI-12-0042","article-title":"The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis","volume":"21","author":"Pettersson","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.cell.2025.07.042_bib60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.07.042_bib61","article-title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.07.042_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.03.017","article-title":"Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants","author":"Lawrence","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.cell.2025.07.042_bib63","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamaoncol.2024.7051","article-title":"Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial","volume":"11","author":"Leone","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2025.07.042_bib64","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.07.042_bib65","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cell.2025.07.042_bib66","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2025.07.042_bib67","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201cHigh-\u201d and \u201cLow-risk\u201d Metastatic Hormone-sensitive Prostate Cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cell.2025.07.042_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13073-022-01080-4","article-title":"Accumulation of copy number alterations and clinical progression across advanced prostate cancer","volume":"14","author":"Grist","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.cell.2025.07.042_bib69","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/sj.bjc.6604951","article-title":"Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study","volume":"100","author":"Berney","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cell.2025.07.042_bib70","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41379-019-0268-y","article-title":"Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments","volume":"32","author":"Kammerer-Jacquet","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cell.2025.07.042_bib71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","article-title":"affy--analysis of Affymetrix GeneChip data at the probe level","volume":"20","author":"Gautier","year":"2004","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cell.2025.07.042_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ygeno.2012.08.003","article-title":"A single-sample microarray normalization method to facilitate personalized-medicine workflows","volume":"100","author":"Piccolo","year":"2012","journal-title":"Genomics"},{"key":"10.1016\/j.cell.2025.07.042_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"2018","journal-title":"J. R. Stat. Soc. Series B Stat Methodol."},{"key":"10.1016\/j.cell.2025.07.042_bib74","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/bioinformatics\/bti525","article-title":"BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis","volume":"21","author":"Durinck","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cell.2025.07.042_bib75","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/nprot.2009.97","article-title":"Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt","volume":"4","author":"Durinck","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.cell.2025.07.042_bib76","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/bioinformatics\/btac153","article-title":"PathwAX II: network-based pathway analysis with interactive visualization of network crosstalk","volume":"38","author":"Ogris","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cell.2025.07.042_bib77","doi-asserted-by":"crossref","first-page":"D587","DOI":"10.1093\/nar\/gkac963","article-title":"KEGG for taxonomy-based analysis of pathways and genomes","volume":"51","author":"Kanehisa","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cell.2025.07.042_bib78","unstructured":"The R Project. (2025). The R Project for Statistical Computing. https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.cell.2025.07.042_bib79","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2589-7500(22)00122-4","article-title":"Data provenance and integrity of health-care systems data for clinical trials","volume":"4","author":"Murray","year":"2022","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.cell.2025.07.042_bib80","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial","volume":"35","author":"Mason","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867425008645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867425008645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:43:44Z","timestamp":1772822624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867425008645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":80,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0092867425008645"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2025.07.042","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2025.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}